Summit Therapeutics stock drops about 5.5% after FDA issues Complete Response Letter on ivonescimab
Summit Therapeutics (SMMT) fell 5.49% after investors reacted to the recent regulatory setback in its lung cancer drug application. The move is supported by strong seller pressure, with the stock trading below all major moving averages.
Highlights
- Summit Therapeutics received a Complete Response Letter from the FDA declining approval of ivonescimab for lung cancer in its first US application.
- The company will start a global Phase III trial named HARMONi-10 studying ivonescimab in non-small cell lung cancer.
- Shares of Summit Therapeutics closed at $9.99, down 5.49%, with strong seller pressure and a five-day forecast range of $8.43 to $11.55.
Regulatory rejection and new trial plans shift investor sentiment
Summit Therapeutics recently received a Complete Response Letter from the FDA, which declined to approve its investigational lung cancer drug, ivonescimab, for its initial US application. Following this development, Summit announced the launch of a new global Phase III clinical trial for ivonescimab targeting non-small cell lung cancer under the HARMONi-10 trial. The company also scheduled a corporate update and operational progress conference call and webcast for November 30, 2026.
Bearish momentum persists as key supports erode amid volatility
SMMT is trading below the 20-, 50-, and 200-day moving averages ($14.79, $15.89, and $16.08), showing clear seller pressure and a bearish structure across all timeframes. The nearest resistance stands at $10.15, with short-term support at $8.43. Momentum signals remain negative, with both the MACD and ADX reflecting a continued sell bias. The Relative Strength Index (RSI) holds neutral, while the Stochastic RSI and CCI are in their oversold zones, suggesting a possible rebound but with sellers still dominating. The Awesome Oscillator further signals downside momentum. Trading activity has remained pressured, with the price nearly at the session low and intraday volatility at 4.12%.
Earlier, analysts noted that Summit Therapeutics remained technically pressured following regulatory delays related to its lung cancer drug ivonescimab. This outlook is reinforced in the current environment, where continued downside momentum places $8.43 as a critical support level to monitor for potential breakdown or consolidation.